Lori A. Leslie, MD

Articles

Inside the Clinic: JTCC Experts Discuss Retreatment With CAR T-Cell Therapy

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy

March 9th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL

March 8th 2022

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Dr. Leslie on Axi-Cel Vs SOC in Relapsed/Refractory Large B-Cell Lymphoma

January 7th 2022

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.

Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL

September 28th 2020

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Dr. Leslie on Sequencing Zanubrutinib in MCL

September 23rd 2020

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.

Dr. Leslie on the Need for Clinical Trials to Address Unmet Needs in MCL

September 16th 2020

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Dr. Leslie on the Role of Zanubrutinib in MCL

September 14th 2020

Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Dr. Leslie on Emerging Therapies in MCL

September 3rd 2020

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Dr. Leslie on Frontline Treatment Options in Follicular Lymphoma

August 24th 2020

Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.

Dr. Leslie on Phase 1b Trial of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

August 22nd 2020

Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.

Dr. Leslie on Current Treatment Options for Relapsed/Refractory MCL

July 23rd 2020

Lori A. Leslie, MD, discusses current treatment options for patients with relapsed/refractory mantle cell lymphoma.

Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL

July 21st 2020

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Dr. Leslie on the Role of BTK Inhibitors in Relapsed/Refractory MCL

July 20th 2020

Lori A. Leslie, MD, discusses the role of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Leslie on the Current Frontline Treatment Landscape in MCL

July 14th 2020

Lori A. Leslie, MD, discusses the current frontline treatment landscape in mantle cell lymphoma.

Dr. Leslie on Remaining Questions to Address in MCL

July 11th 2020

Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.

Dr. Leslie on the Benefits With Zanubrutinib in MCL

July 9th 2020

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib

January 8th 2020

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).

Dr. Leslie Discusses Advancements in Mantle Cell Lymphoma

April 28th 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses advancements in mantle cell lymphoma.